Amgen

About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. We focus on four therapeutic areas: oncology, inflammation, general medicine, and rare disease. Our medicines typically address diseases for which there are limited treatment alternatives, or they are medicines that provide a viable option to what is otherwise available. Click here to learn more about Amgen’s pipeline. We have helped shape the scientific world’s understanding of certain disease processes, and we have engineered new types of therapeutic platforms. As a company, we could not have accomplished all of this were it not for our deep commitment to building a culture that embraces science and innovation—a culture that continues to shape who we are today.